Derangements in bone mineral parameters and bone mineral density in south Indian subjects on antiepileptic medications

George Koshy, Ron Thomas Varghese, Dukhabandhu Naik, Hesargatta Shyamsunder Asha, Nihal Thomas, Mandalam Subramaniam Seshadri, Mathew Alexander¹, Maya Thomas¹, Sanjith Aaron¹, Thomas Vizhalil Paul
Departments of Endocrinology, Diabetes and Metabolism and Neurological Science, Unit-III, Christian Medical College, Vellore, Tamil Nadu, India

Abstract

Background: Although there are reports describing the association of alternations of bone and mineral metabolism in epileptic patients with long-term anticonvulsant therapy, there are only limited Indian studies which have looked at this aspect. Objectives: This study was done to compare the prevalence of changes in bone mineral parameters and bone mineral density (BMD) in ambulant individuals on long-term anticonvulsant therapy with age- and body mass index (BMI)-matched healthy controls. Materials and Methods: There were 55 men (on medications for more than 6 months) and age- and BMI-matched 53 controls. Drug history, dietary calcium intake (DCI), and duration of sunlight exposure were recorded. Bone mineral parameters and BMD were measured. Results: The control group had a significantly higher daily DCI with mean ± SD of 396 ± 91 mg versus 326 ± 101 mg (P = 0.007) and more sunlight exposure of 234 ± 81 vs 167 ± 69 min (P = 0.05). BMD at the femoral neck was significantly lower in cases (0.783 ± 0.105 g/cm²) when compared to controls (0.819 ± 0.114 g/cm²). Majority of the patients (61%) had low femoral neck BMD (P = 0.04). There was no significant difference in the proportion of subjects with vitamin D deficiency (<20 ng/mL) between cases (n = 32) and controls (n = 37) (P = 0.234). Conclusions: Vitamin D deficiency was seen in both the groups in equal proportions, highlighting the existence of a high prevalence of this problem in India. Low femoral neck BMD found in cases may stress the need for supplementing calcium and treating vitamin D deficiency in this specific group. However, the benefit of such intervention has to be studied in a larger proportion of epileptic patients.

Key Words
Anticonvulsants, bone mineral density, epilepsy, vitamin D

Introduction

In India, the prevalence rate of epilepsy has been estimated to be 1%. The urban-rural divide for this disease is alarming with studies done in Bengaluru suggesting that the prevalence may be twice as much in rural when compared to urban regions. A substantial amount of healthcare needs of most of the rural population is met by hospitals in primary and secondary care settings. Phenytoin and sodium valproate continue to be the major antiepileptic drugs (AEDs) being used in India. The adverse effects of long-term AEDs on bone and mineral metabolism was initially reported by Kruse in 1968, who observed radiological evidence of rickets and low serum calcium levels in 15% of a German pediatric outpatient population with epilepsy. It has also been observed that these changes were seen as early as within 60 days of starting therapy. These findings of derangements in calcium and phosphate metabolism in patients with anticonvulsant therapy have been reported in epileptic populations throughout the world with prevalence rates ranging from 3 to 30%. AEDs like phenytoin, carbamazepine, and sodium valproate induce hepatic oxidase activity through microsomal enzymes (p 450) in the liver. This in turn increases the metabolism of vitamin...
D and thus can lead to hypocalcemia, hypophosphatemia, low vitamin D, and high parathyroid hormone (PTH) levels. The fracture risk in these patients is heightened much more by unsteadiness in gait, fall, and limited mobility. Biochemical changes described earlier are frequently seen in 30-40% of patients, in majority of these subjects the changes are either mild or subclinical in nature. The effect of AEDs on bone can also be modified by a number of factors like exposure to sunlight and poor dietary intake of calcium and vitamin D.[13] Fractures in these patients also place a considerable economic burden.[13]

However, there are no studies in this regard in the southern Indian population with regards to epilepsy. This is relevant in an Indian context, since a high prevalence of vitamin D deficiency has been reported widely in the normal and diseased population.[14-16]

The present study attempts to determine as to whether poor dietary calcium intake (DCI), decreased sunlight exposure, hypocalcemia, hypophosphatemia, low vitamin D, and low bone mineral density (BMD) occur with greater frequency in males who are on long-term anticonvulsant therapy.

**Materials and Methods**

**Design: A prospective cross-sectional study**

Fifty-five ambulant male patients with epilepsy between 20 and 50 years of age, who were on at least one of the enzyme inducing anticonvulsants (phenytoin, phenobarbitone, or carbamazepine) for more than 6 months, attending the epilepsy clinic of the neurology department, were selected for the study. Fifty-three healthy subjects, matched for age and body mass index (BMI) were recruited from the community health database of the institution, as controls. Subjects with concomitant hepatic or renal diseases, malabsorption, and on other medications like corticosteroids, which could potentially affect the vitamin D and calcium metabolism were excluded.

A detailed clinical history, type of seizure, pattern of medications like type and duration of AEDs, and a physical assessment was conducted in all subjects. The daily intake of calcium was estimated based on the duration of exposure to sunlight, amount of clothing, and extent of body surface area exposed to sunlight as detailed in an earlier study.[14] Physical assessment included evaluation for any specific features of osteomalacia, such as fractures or proximal muscle weakness. Informed consent was obtained from all the subjects and the study was approved by the institutional review board (IRB number 6203 dated 17/04/2009).

An overnight fasting blood sample was obtained for estimation of serum calcium, phosphate, albumin, alkaline phosphatase, creatinine, 25-hydroxyvitamin D (25(OH)D), and intact PTH. A radioimmunoassay (DiaSorin, Stillwater, Minnesota) was used for determination of vitamin D levels. The analytical sensitivity of this assay, when defined as the lowest quantity that differentiated from the zero standard (N = 20) has been shown to be 1.5 ng/mL. The intra-assay coefficient of variation was 5.5% at a vitamin D level of 15.6 ng/mL and 9.3% at a vitamin D level of 52.5 ng/mL. Vitamin D deficiency has been defined by most experts as a vitamin D level of less than 20 ng/mL (50 nmol/L) and a level of 30 ng/mL or greater has been considered to indicate sufficient vitamin D and values between 20 and 30 ng/dL have been considered as indicative of vitamin D insufficiency. Intact PTH was measured by chemiluminescence method using Immulite analyzer 2000 (normal - 8-50 pg/mL). Other biochemical parameters were measured in a fully automated and computerized microanalyzer (Hitachi model 911; Boehringer Mannheim, Mannheim, Germany). The intra- and inter-assay coefficients of variation for these analyses were 1-5%.

BMD was assessed by using the Hologic Dxa machine (QDR 4500; Hologic Inc, Waltham, Massachusetts) at the lumbar spine (L1-L4) and the femoral neck. The reference population consisted of normal Caucasian subjects from the manufacturer’s database. The reference population (manufacturer's database) was Caucasian in origin for defining Z-scores. A Z-score less than two standard deviations (SDs) below the mean of the reference population was described as a low BMD.[17] The precision was 2% at both measured sites (spine and neck of femur).

**Sample size calculation**

In an earlier study, vitamin D status was estimated in a group of ambulatory patients receiving anticonvulsants therapy and the mean difference of vitamin D level was found to be 6.2 ng/mL when compared between cases and controls. Vitamin D levels (mean ± SD) in cases was 28.2 ± 10.3 and 34.4 ± 12.7 ng/mL in controls.[11] In order to detect a difference of 6.2 ng/mL with a 95% confidence and a power of 80%, a case-control study with 52 patients on AEDs for more than 6 months and 52 healthy individuals were to be selected.

**Statistical analysis**

An analysis was done using the Statistical Package for Social Sciences (SPSS) version 17 software package. An independent sample t-test was used to compare the means of two continuous variables if the distribution was normal, and nonparametric tests were used otherwise. A correlation between two continuous, parametric variables was done using Pearson’s correlation. Chi-square tests and Fisher’s exact test were used where indicated.

**Results**

A total of 55 ambulant epileptic men and 53 age- and BMI-matched controls were studied. Baseline demography, biochemical profile, and BMD of both the groups are shown in [Table 1]. The mean age (SD) in cases was 27.7 (7.9) and 29.6 (7.7) years in controls.

Of the 55 epileptic patients, 35 were diagnosed to have idiopathic epilepsy. Thirteen had partial onset seizure leading onto secondary generalization and seven presented with the features of temporal lobe epilepsy or focal seizures. Thirty-one (56.4%) were on monotherapy (23 on phenytoin, six on carbamazepine, and two on phenobarbitone) and 24 (43.6%) were on polytherapy of more than one drug. The median duration of treatment was 15 months.
The control group had a significantly higher DCI (396 ± 91 vs 326 ± 101 mg; \( P = 0.007 \)) and sunlight exposure (234 ± 81 vs 167 ± 69 min; \( P = 0.05 \)). The mean serum phosphate level in cases was 3.8 mg/dL, which was significantly lower (\( P = 0.028 \)) when compared to those seen in controls (4.3 mg/dL); however, hypophosphatemia (<2.5 mg%) was detected only in one patient in the study group but none in the control group. The mean (SD) vitamin D level in the study subjects was 19 ± 7.5 and 17 ± 7.2 ng/mL in controls (\( P = 0.113 \)). Vitamin D deficiency (<20 ng/mL) was found in 32 (58.1%) cases and 37 (69.8%) controls (\( P = 0.234 \)).

The BMD at the femoral neck was significantly lower (\( P = 0.041 \)) in cases (0.783 ± 0.105 g/cm²) when compared to controls (0.819 ± 0.114 g/cm²) and significantly more proportion of patients had low femoral neck BMD (\( P = 0.04 \)). There was however, no difference in the proportion of patients having low BMD among cases and controls at spine [Table 2].

The correlations between BMD and various parameters were assessed in both cases and controls. BMI had a significant positive correlation with BMD at the spine and femoral neck in both cases and controls (spine \( r = 0.5, P = 0.0001 \); femoral neck \( r = 0.4, P = 0.006 \) in cases; spine \( r = 0.5, P = 0.001 \); and femoral neck \( r = 0.4, P = 0.006 \) in controls) and there were no correlations between other parameters and BMD.

A negative correlation was seen between PTH and vitamin D among cases and controls, which was significant among cases alone (\( r = -0.4, P = 0.005 \)). A positive correlation found between duration of sunlight exposure and 25(OH)D level was significant only among cases (\( r = 0.3, P = 0.013 \)).

The BMD - spine g/cm² 0.91 2 (0.108) 0.936 (0.122) 0.284 (min/day)
BMI (kg/m²) 21.41 (4) 22.1 (3.8) 0.35
Sunlight exposure r = 0.4, P = 0.006 in cases; spine r = 0.5, P = 0.001; and femoral neck r = 0.4, P = 0.006 in controls

### Table 1: Baseline characteristics of cases and controls

| Characteristic | Cases (N = 55) | Controls (N = 53) | \( P \)-value |
|---------------|---------------|------------------|--------------|
| Age (years)   | Mean (SD)     | Mean (SD)        | 0.11         |
| BMI (kg/m²)   | 21.41 (4)     | 22.1 (3.8)       | 0.35         |
| Sunlight exposure (min/day) | 167 (69)       | 234 (81)         | 0.05         |
| Dietary calcium mg/day | 326 (101)     | 396 (148)        | 0.007        |
| BMD - spine g/cm² | 0.912 (0.108) | 0.936 (0.122) | 0.284        |
| BMD - femoral neck (g/cm²) | 0.783 (0.105) | 0.819 (0.114) | 0.041        |
| Corrected calcium (mg/dL) | 8.4 (0.3)     | 8.5 (0.3)        | 0.90         |
| Phosphate (mg/dL) | 3.8 (0.6)    | 4.3 (0.6)        | 0.028        |
| Albumin (g/dL) | 4.5 (0.2)     | 4.5 (0.3)        | 0.632        |
| Creatinine (mg/dL) | 0.8 (0.1)   | 0.9 (0.4)        | 0.144        |
| Alkaline phosphatase (U/L) | 86 (21)   | 101 (69)        | 0.140        |
| 25-hydroxy vitamin D (ng/mL) | 19 (7.5)    | 17 (7.2)        | 0.113        |

Low serum phosphate

The lower serum phosphate level observed in our subjects with epilepsy has also been demonstrated in other studies.[20-22] However, there was no difference in the proportion of patients having hypophosphatemia between cases and controls.

Previous studies have shown that anywhere from 25 to 50% differently-abled children[20] or children on antiepileptic medications[22] had hypophosphatemia.

Hypophosphatemia may be secondary to vitamin D deficiency and also due to the direct effect of antiepileptic drugs on renal tubules in those on long-term treatment.[23,24] However, many subjects on chronic anticonvulsant therapy may not develop significant hypophosphatemia. This has been documented in earlier studies. Kruse et al., noted a higher tubular transportation rate of phosphate despite secondary hyperparathyroidism in patients on anticonvulsant therapy.[25] They described a normal rise in urinary cyclic adenosine monophosphate (AMP) excretion without concomitant increase in the excretion of phosphate in the urine after the infusion of parathyroid extract in children on phenytoin and phenobarbitone treatment, resembling pseudohypoparathyroidism type II.

### Table 2: Proportion of subjects with low bone mineral density in either group

| Characteristics | Cases (55) | Controls (53) | Significance, \( P \)-value |
|----------------|-----------|--------------|--------------------------|
| Lumbar spine   | 39 (70)   | 32 (60)      | 0.31                     |
| Neck of femur  | 34 (61)   | 22 (41)      | 0.04                     |

**Discussion**

This is the first such study to the best of our knowledge from southern India which looked into the changes in bone metabolic parameters and bone density in patients who were on antiepileptic therapy. Subjects who were on antiepileptic medications had a trend towards a low calcium intake, sunlight exposure, serum phosphate, and femoral neck BMD. The number of subjects with vitamin D deficiency was the same between cases and controls.

**Dietary calcium intake**

DCI was lower than the recommended daily allowance in both the groups. There was a significantly lower intake of dietary calcium in patients on anticonvulsant therapy. Several other studies from various parts of India have documented a similar trend towards a low calcium intake in healthy subjects[19]. Harinarayan et al., in a study conducted in a rural Indian population had found that the DCI was lower than the recommended daily allowance.[19] Moreover, calcium deficiency appears to be worsened by dietary factors like high phytate content in the south Indian diet which also contribute to a reduction in calcium absorption.[19] In the setting of nutritional calcium deficiency, PTH levels are raised in an attempt to convert 25(OH)D to 1,25-dihydroxyvitamin D to increase the calcium absorption. However, in patients with low 25(OH)D at baseline, the resultant secondary hyperparathyroidism only results in more bone resorption.

**Low serum phosphate**

The lower serum phosphate level observed in our subjects with epilepsy has also been demonstrated in other studies.[20-22] However, there was no difference in the proportion of patients having hypophosphatemia between cases and controls.

Vitamin D levels

Vitamin D deficiency is quite common in India subcontinent.[14,19] Several studies from different parts of India in various subgroup of population including health volunteers, pregnant women, school children, hospital staff, and even army personnel show very high prevalence of vitamin D deficiency.[16] Our study showed low vitamin D in both cases and controls and the difference between these two groups was not significant.
Arya et al., studied healthy volunteers from north India. The mean 25(OH)D in these volunteers was 12.3 ng/mL. Only one-third was vitamin D sufficient with a cutoff > 15 ng/mL.[26] Other studies have subsequently shown that healthy individuals, pregnant women, doctors, and nurses have extremely low vitamin D levels as opposed to depigmented women who have high normal levels.[27] There is a greater magnitude of normal vitamin D levels in those from rural compared to urban areas; however, the difference is relatively small.[19]

The proposed reasons for high prevalence of vitamin D deficiency among Indian population include skin pigmentation, clothing pattern, a lower, duration of sunlight exposure, genetic factors, and vegetarian diet.[14,15,19] Enzyme inducing properties of AEDs like phenytoin, carbamazepine, and phenobarbitone would have further contributed to the preexisting problem. Rapid vitamin D catabolism has been defined as the principal mechanism responsible vitamin D deficiency and osteomalacia in those patients.[22]

The duration of sunlight exposure had a positive correlation with vitamin D only in cases. The lack of correlation in controls is probably due to many factors including reporting bias and skin pigmentation.[14] Other studies have demonstrated significant correlation between sunlight exposure and vitamin D levels.[20]

Our study has shown higher PTH level among subjects with AEDs which is probably due to a combination of many factors such as vitamin D deficiency and poor DCI. Elevated PTH levels could be detrimental to bone in epileptic patients as it can increase the rate of bone resorption. Sahota et al., have described a blunted response of PTH in nearly two-thirds of vitamin D deficient individuals in whom secondary hyperparathyroidism was not seen. This may explain the lack of a significant correlation between vitamin D and PTH in the control group.[29]

**Bone mineral density**

BMD was lower in patients on anticonvulsants and was significantly lower ($P = 0.041$) at the neck of femur. Kulak et al., studied BMD in a group of patients from Brazil on AEDs and 63.5% of patients had a T-score of less than -1.0 in at least in one site.[11] Farhat et al., noticed similar changes in patients who were on anticonvulsant therapy for more than 6 months duration.[30] A progressive decline in femoral neck BMD has been reported over a period of 1 year, in subjects on anticonvulsant therapy.[31]

Patients using AEDs for more than 2 years and particularly those taking enzyme-inducing AEDs and those older than 40 years, have significantly lower BMD at relevant fracture risk sites.[32]

Amongst the various correlations, only BMI correlated with BMD (both at femoral neck and spine) in both cases and controls, which is a well-established occurrence.[14,33]

There have been reports of an increased incidence and risk of fractures in patients on chronic antiepileptic medications.[34,35] This would mean that the low BMD could also translate into clinical outcomes like fractures and demand urgent attention and regular supplementation with vitamin D and calcium which is not a current clinical practice in India, to avoid fractures.[36]

**Limitations**

Vitamin D deficiency is more prevalent in the Indian population, and hence the small sample size failed to demonstrate any effect of antiepileptic medications on vitamin D. A larger sample would have brought out the differences more clearly. In addition, dichotomy observed with regards to changes in BMD between spine and femoral neck could not be further evaluated by bone histomorphometry for ethical reasons as it is an invasive procedure warranting bone biopsy from different sites.

**Conclusions**

In the present study, many of the patients (58.1%) on AEDs had low vitamin D levels. Simultaneously, these patients were found to have low DCI, inadequate exposure to sunlight and low BMD at the femur. This suggests that patients on antiepileptic medication are more prone to develop low BMD and this may stress the need for supplementing calcium and vitamin D deficiency in this specific group. However, the benefit of such intervention has to be studied in a larger cohort of epileptic patients.

**References**

1. Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631-6.
2. Gounie-Devi M, Gururaj G, Satishchandra P, Subbakkrisna DK. Prevalence of neurological disorders in Bangalore, India: A community- based study with a comparison between urban and rural areas. Neuroepidemiology 2004;23:261-8.
3. Sil A, Das K, Das NK, Chakraborty D, Mazumdar G, Tripathi SK. Use of anti-epileptic drugs in a tertiary care hospital of Eastern India with emphasis on epilepsy due to neurocysticercosis. Indian J Pharmacol 2012;44:106-10.
4. Kruse R. Osteopathien bie antiepilaptischer Langeihterapie. Montselslefe Kinderherlildt 1968;116:378-81.
5. Krishnamoorthy G, Nair R, Sundar U, Kini P, Shrivastava M. Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: A prospective study. Neurl India 2010;58:213-9.
6. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970;4:7-36.
7. Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-4.
8. Bouillon R, Reynaert J, Claes JH, Lissens W, De Moor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975;41:1130-5.
9. Berry JL, Mawer EB, Walker DA, Carr P, Adams PH. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients. In: Oxley J, Jann J, Meinardi H, editors. Antiepileptic Therapy: Chronic Toxicity of Antiepileptic Drug. Scotland: Raven Press; 1983. p. 185-92.
10. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin...
11. Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, de Paola L, Boguszewski CL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 2004;62:940-8.

12. Goraya JS, Gupta PN, Gupta RK, Bahadur R, Parmar VR. Anticonvulsant induced osteomalacia. Indian Pediatr 2000;37: 325-9.

13. Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, et al. Economic burden of epilepsy in India. Epilepsia 2001;42:1052-60.

14. Paul TV, Thomas N, Seshadri MS, Oormen R, Jose A, Mahendri NV. Prevalence of osteoporosis in ambulatory postmenopausal women from a semiurban region in Southern India: Relationship to calcium nutrition and vitamin D status. Endocr Pract 2008;14:665-71.

15. Paul TV, Asha HS, Thomas N, Seshadri MS, Rupali P, Abraham OC, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocr Pract 2010;16:547.

16. Harinarayan CV, Joshi SR. Vitamin D status in India — its implications and remedial measures. J Assoc Physicians India 2009;57:40-8.

17. The Writing Group for the ISCD Position Development Conference. Position Statement Diagnosis of Osteoporosis in Men, Premenopausal Women, and Children. J Clin Densitom 2004;7:17-26.

18. Nutrient requirements and recommended dietary allowances for Indians. A report of the expert group of the Indian Council of Medical Research. 2009. National institute of nutrition. Available from: http://icmr.nic.in/ final/rda-2010.pdf [Last accessed 2nd October, 2013]

19. Harinarayan CV, Ramakrishna T, Prasad UV, Sudhakar D, Srinivasarao PV, Sarma KV, et al. High prevalence of low dietary calcium, high phytate consumption, and vitamin D deficiency in healthy south Indians. Am J Clin Nutr 2007;85:1062-7.

20. Tolman KG, Jubiz W, Sannella J, Madsen JA, Belsey RE, Goldsmith RS, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975;56: 45-50.

21. Hahn TJ, Hendin BA, Scharp CR, Boisseau VC, Haddad JG. Serum 25-hydroxycalciﬁerol levels and bone mass in children on chronic anticonvulsivant therapy. N Engl J Med 1976;292: 550-4.

22. Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC. Antiepileptic drugs and bone metabolism in children: Data from 128 patients. J Child Neurol 2013;28:176-83.

23. Liamis G, Milionis HJ, Eliaf M. Medication-induced hypophosphatemia: A review. QJM 2010;103:449-59.

24. Verrotti A, Greco R, Pascarella R, Matera V, Morgese G, Chiarelli F. Renal tubular function in patients receiving anticonvulsant therapy: A long-term study. Epilepsia 2000;41:1432-5.